Literature DB >> 17093022

Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Pushpendra Singh1, Clement Wesley, G P S Jadaun, Sunil Kumar Malonia, R Das, P Upadhyay, J Faujdar, P Sharma, P Gupta, Abhay Kumar Mishra, Kalpana Singh, D S Chauhan, V D Sharma, U D Gupta, K Venkatesan, V M Katoch.   

Abstract

Pyrazinamide (PZA) is an important first-line antituberculosis drug because of its sterilizing activity against semidormant tubercle bacilli. In spite of its very high in vivo activity, its in vitro activity is not apparent unless an acidic environment is available, which makes PZA susceptibility testing difficult by conventional methods. The present study was, therefore, planned to assess the performance of the colorimetric BacT/ALERT 3D system and compare the results with those from conventional tests, i.e., the Löwenstein-Jensen (LJ) proportion method (pH 4.85) and Wayne's pyrazinamidase (PZase) assay, using 107 clinical isolates. The concordance among all of these tests was 89.71% after the first round of testing and reached 92.52% after resolution of the discordant results by retesting. Prolonged incubation of the PZase tube for up to 10 days was found to increase the specificity of the PZase test. The concordances between LJ proportion and BacT/ALERT 3D, LJ proportion and the PZase assay, and BacT/ALERT 3D and the PZase assay were found to be 99.06%, 93.46%, and 92.52%, respectively. Using the LJ results as the gold standard, the sensitivities of BacT/ALERT 3D and the PZase assay were 100 and 82.85%, respectively, while the specificity was 98.61% for both of the tests. The difference between the sensitivities of BacT/ALERT 3D and the PZase assay was significant (P = 0.025). The mean turnaround times for the detection of resistant and susceptible results by BacT/ALERT 3D were 8.04 and 11.32 days, respectively. While the major limitations associated with the PZase assay and the LJ proportion method are lower sensitivity in previously treated patients and a longer time requirement, respectively, the BacT/ALERT 3D system was found to be rapid, highly sensitive, and specific.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093022      PMCID: PMC1828947          DOI: 10.1128/JCM.00951-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Comparison of the ESP and BACTEC systems for testing susceptibilities of Mycobacterium tuberculosis complex isolates to pyrazinamide.

Authors:  Vincent J LaBombardi
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Evaluation of indirect susceptibility testing of Mycobacterium tuberculosis to the first- and second-line, and alternative drugs by the newer MB/BacT system.

Authors:  Angela Maria Werneck Barreto; Joselba Borges Melo Araújo; Reginalda Ferreira de Melo Medeiros; Paulo César de Souza Caldas
Journal:  Mem Inst Oswaldo Cruz       Date:  2003-10-29       Impact factor: 2.743

3.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

4.  Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar.

Authors:  K D Stottmeier; R E Beam; G P Kubica
Journal:  Am Rev Respir Dis       Date:  1967-11

5.  Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Y Zhang; A Scorpio; H Nikaido; Z Sun
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

6.  Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity.

Authors:  W R Butler; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

7.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria.

Authors:  L G Wayne
Journal:  Am Rev Respir Dis       Date:  1974-01

8.  Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.

Authors:  S Rüsch-Gerdes; C Domehl; G Nardi; M R Gismondo; H M Welscher; G E Pfyffer
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

9.  Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test.

Authors:  Akio Aono; Kazue Hirano; Sonomi Hamasaki; Chiyoji Abe
Journal:  Diagn Microbiol Infect Dis       Date:  2002-12       Impact factor: 2.803

10.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

View more
  20 in total

1.  Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Niuris C Mirabal; Sergio L Yzquierdo; Dihadenys Lemus; Mariela Madruga; Yoslaine Milián; Miguel Echemendía; Howard Takiff; Anandi Martin; Patrick Van der Stuyf; Juan Carlos Palomino; Ernesto Montoro
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

2.  Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria.

Authors:  Karine Soetaert; Céline Rens; Xiao-Ming Wang; Jacqueline De Bruyn; Marie-Antoinette Lanéelle; Françoise Laval; Anne Lemassu; Mamadou Daffé; Pablo Bifani; Véronique Fontaine; Philippe Lefèvre
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

3.  Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.

Authors:  Emily R Driver; Gavin J Ryan; Donald R Hoff; Scott M Irwin; Randall J Basaraba; Igor Kramnik; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing.

Authors:  Kingsley King-Gee Tam; Kenneth Siu-Sing Leung; Gilman Kit-Hang Siu; Kwok-Chiu Chang; Samson Sai-Yin Wong; Pak-Leung Ho; Eunice Ka-Chun Leung; Wing-Cheong Yam
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

5.  Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Authors:  J Werngren; E Sturegård; P Juréen; K Ängeby; S Hoffner; T Schön
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

6.  Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.

Authors:  R I Calderón; G E Velásquez; M C Becerra; Z Zhang; C C Contreras; R M Yataco; J T Galea; L W Lecca; A L Kritski; M B Murray; C D Mitnick
Journal:  Int J Tuberc Lung Dis       Date:  2017-08-01       Impact factor: 2.373

Review 7.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

8.  Improved Detection by Next-Generation Sequencing of Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates.

Authors:  Nontuthuko E Maningi; Luke T Daum; John D Rodriguez; Matsie Mphahlele; Remco P H Peters; Gerald W Fischer; James P Chambers; P Bernard Fourie
Journal:  J Clin Microbiol       Date:  2015-09-16       Impact factor: 5.948

9.  Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.

Authors:  Jirarut Jonmalung; Therdsak Prammananan; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  BMC Microbiol       Date:  2010-08-20       Impact factor: 3.605

10.  Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria.

Authors:  Céline Rens; Françoise Laval; Mamadou Daffé; Olivier Denis; Rosangela Frita; Alain Baulard; Ruddy Wattiez; Philippe Lefèvre; Véronique Fontaine
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.